Novel Immunooncology Agent, Small-Molecule Ror. Agonist Lyc-55716: Tumor Selection Process For Phase Iia Expansion And Rationale For Clinical Evaluation In Ovarian Cancer Following Phase I Dose Finding

Objective: Translational and bioinformatics assessments were performed to support the inclusion of ovarian cancer (OC) patients in a phase 2a trial of the retinoic acid receptor–related orphan receptor γt (RORγ) agonist LYC-55716. RORγ is the master transcription factor regulating type 17 effector T cell differentiation and function. Synthetic RORγ agonists modulate gene expression in immune cells to enhance effector functions and decrease Treg and checkpoint pathways. RORγ agonists have shown activity as mono- and combination therapy in syngeneic tumor models.